Digbi Health’s Gut Biome and DNA-Based Weight Loss and Diabetes Management Program Launches with Blue Shield of California

MOUNTAIN VIEW, Calif., Nov. 25, 2019 /PRNewswire/ — Digbi Health’s clinically validated, personalized obesity, pre-diabetes and type 2 diabetes management program tailored to a person’s DNA, gut biome, lifestyle preferences, and ethnicity is now available to Blue Shield of California members on the health plan’s Wellvolution platform. A digital therapeutics and community health network that is the largest in the industry, Wellvolution was created in collaboration with Solera Health to help consumers holistically manage their health.

Digbi Health’s availability on the Wellvolution platform gives Blue Shield members access to a powerful, proven, DNA and gut microbiome-based precision care and personalized lifestyle medicine tool that is tailored to their unique biology and lifestyle.

“Doctors and payers understand that obesity and diabetes are multifactorial diseases, and one-size-fits-all diet and exercise weight loss and diabetes programs do not deliver patient engagement and sustained health results,” said Ranjan Sinha, CEO, and founder of Digbi Health. “We are the first company to operationalize a DNA and gut microbiome-based prescription-grade platform for doctors and payers to deliver weight loss and diabetes programs at scale.”

“Digbi Health is a strong fit for Wellvolution, which is designed to drive sustained engagement and outcomes by matching members to the program that best meets their needs,” said Brenda Schmidt, CEO, Solera Health.

Blue Shield of California, an innovative health insurer with 4.3 million members, launched Wellvolution in June. The digital therapeutics platform, powered by Solera, features a selection of about 70 digital health apps (out of more than 300,000 currently available in the Apple App Store), curated for clinical effectiveness and consumer preference.

About Digbi Health
Digbi Health is a first-of-its-kind precision digital therapeutics (pDTx) company that offers a prescription-grade digitally delivered personalized obesity and diabetes management program based on an individual’s gut biome, DNA, blood markers, and lifestyle factors. Digbi Health and members of its precision care MD network are committed to empowering people to take control of their own health and wellness. Digbi Health is prescribed by doctors, health care providers, and insurance companies. Digbi Health is currently conducting three Institutional Review Board approved human studies. Learn more at www.digbihealth.com. Or follow us on LinkedIn, Facebook or Twitter.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/digbi-healths-gut-biome-and-dna-based-weight-loss-and-diabetes–management-program-launches-with-blue-shield-of-california-300964553.html

SOURCE Digbi Health

Staff

Recent Posts

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

11 hours ago

Best GLP-1 Weight Loss Shot (2026): Direct Meds Reviews Prescription Access Pathways as New GLP-1 Formats Expand

LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…

14 hours ago

Nutri Derma Guard Skin Tag Remover Ingredients Investigated: 2026 Analysis Examines Formulation And Consumer Disclosures

Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…

14 hours ago

SleepZee Mouth Guard Legitimacy Examined: 2026 Consumer Analysis Investigates Anti-Snoring Device Claims and Company Transparency

Independent examination investigates SleepZee's moldable customization approach, medical-grade material claims, and manufacturer disclosure practices for…

14 hours ago